Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Acalypha australis** is a herbaceous annual plant in the family Euphorbiaceae, commonly known as Asian copperleaf or copperleaf. It is traditionally used in Chinese medicine for its purported effects on hemostasis (stopping bleeding), detoxification, heat clearance, and has historical usage for treating conditions like diarrhea, dysentery, snakebite, nosebleed, dermatitis, ulcerative colitis, and cough[1][2][3][5][6][7][8]. Pharmacological studies suggest its mechanisms may include anti-inflammatory effects (notably via NF-κB pathway inhibition), anti-obesity effects (through regulation of adipogenesis by suppressing PPARγ and CEBP/α expression), as well as possible antibacterial, antidiabetic, anticancer, and detoxifying actions[1][3][7]. Recent animal studies indicate potential benefit in mitigating ulcerative colitis and improving metabolic parameters related to obesity and lipid metabolism[1][3]. Its active constituents include flavonoids, with individual compounds such as 4-hydroxybenzoic acid methyl ester, 3-methoxy-4-hydroxybenzoic acid, and protocatechuic acid proposed to mediate some effects[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acalypha australis.